L&C Bio Co., Ltd. (290650) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for L&C Bio Co., Ltd. (290650:KRX), powered by AI.

Current Price
₩76,200
P/E Ratio
-14.9
Market Cap
2.1T
Sector
Healthcare
What is the L&C Bio Co., Ltd. stock price forecast?

L&C Bio Co., Ltd. is currently trading at ₩76,200. View real-time AI analysis on Alpha Lenz.

What is L&C Bio Co., Ltd. insider trading activity?

View the latest insider trading data for L&C Bio Co., Ltd. on Alpha Lenz.

What is L&C Bio Co., Ltd.'s P/E ratio?

L&C Bio Co., Ltd.'s P/E ratio is -14.9.

L&C Bio Co., Ltd.

KRX · 290650
₩76,200-700(-0.91%)Market closedKRX regular session 09:00–15:30 KST
Ask about L&C Bio Co., Ltd.'s future dividend policy...
Alpha Chat Insight

L&C Bio Co., Ltd. trades at a P/E of -14.9 (undervalued) with modest ROE of -57.3%. 3Y revenue CAGR of 17.6% highlights clear growth momentum.

Ask for details

Company Overview

L&C Bio Co., Ltd. is a prominent player in the biotechnology and life sciences sector, specializing in the research, development, and commercialization of regenerative medicine solutions. The company's primary focus lies in the development of innovative products aimed at promoting skin rejuvenation and wound healing. A key aspect of L&C Bio's product lineup includes advanced biomaterials derived from collagen, which play a crucial role in medical and cosmetic applications. L&C Bio Co., Ltd. significantly impacts the healthcare industry by providing state-of-the-art solutions that cater to both medical professionals and end consumers seeking effective treatments. With a strong emphasis on R&D, the company collaborates with various research institutions and invests heavily in technological advancements to maintain a competitive edge. L&C Bio's importance in the market is underscored by its commitment to enhancing patient outcomes and improving the quality of life through cutting-edge biotechnological innovations.

CEO이환철, 이재호 (각자 대표이사)
SectorHealthcare
IndustryMedical Devices
Employees130

Company Statistics

FY 2025

Profile

₩2,055,091,444,800Market Cap
₩85,476,414,990Revenue
26.97MShares Out
130Employees

Margins

53.10%Gross
17.29%EBITDA
5.17%Operating
-187.23%Pre-Tax
-161.74%Net

Valuation

-14.87P/E
10.37P/B
24.04EV/Sales
143.93EV/EBITDA
-459.67P/FCF

Growth (CAGR)

17.59%Rev 3Yr
20.99%Rev 5Yr
-22.49%Op Inc 3Yr
-9.63%Op Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-29.66%ROA
-57.27%ROE
-33.07%ROIC

Financial Health

₩30,887,981,150Cash & Cash Equivalents
₩217,215,695,650Net Debt
118.98%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

L&C Bio Co., Ltd. (ticker: 290650) is a company listed on KRX in the Healthcare sector (Medical Devices). It has approximately 130 employees. Market cap is $2.1T.

The current price is ₩76,200 with a P/E ratio of -14.87x and P/B of 10.37x.

ROE is -57.27% and operating margin is 5.17%. Annual revenue is $85.5B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
L&C Bio Co., Ltd. (290650) Stock Forecast 2026 ₩76,200 — Price, Financials & Analyst Targets | Alpha Lenz